ITGB6 Antibody

What is ITGB6 and what biological role does it play?

ITGB6 is the beta-6 subunit of integrin that pairs with integrin alpha-V (ITGAV) to form the heterodimeric cell surface protein integrin αvβ6. This complex functions as a receptor for fibronectin and cytotactin, recognizing the R-G-D sequence in its ligands. Physiologically, ITGB6 impacts inflammation and wound healing processes through its expression in epithelial tissues, contributing to tissue integrity and function . Most significantly, integrin αvβ6 serves as one of the major physiological activators of transforming growth factor-β (TGF-β), mediating R-G-D-dependent release of TGF-β1 from regulatory Latency-associated peptide (LAP) . This activation plays a key role in immunomodulation within the tumor microenvironment.

How is ITGB6 normally expressed in tissues and how does this change in cancer?

ITGB6 is expressed at very low levels in most organs during tissue homeostasis but shows highly upregulated expression during tumorigenesis in many cancers of epithelial origin . Studies reveal significant upregulation in head and neck squamous cell carcinoma (median fold change 2.70, p<0.0001), bladder urothelial carcinoma (FC 2.41, p<0.001), cholangiocarcinoma (FC 5.33, p<0.01), and esophageal carcinoma (FC 2.72, p<0.03) compared to normal tissue . Interestingly, lung adenocarcinoma (FC 0.77, p<0.04) and lung squamous cell carcinoma (FC 0.55, p<0.0001) showed downregulation of ITGB6 compared to normal tissue . The upregulation pattern demonstrates its potential role as a biomarker in specific cancer types.

What methodological approaches can be used to detect ITGB6 expression in tissue samples?

Research methodology for ITGB6 detection frequently employs immunohistochemistry (IHC) using specific antibodies. For quantification, a scoring system based on both staining intensity and proportion of positive cells is commonly used. A standardized approach involves scoring the proportion of positive tumor cells (<10% scored 0; 10-30% scored 1; 30-70% scored 2; >70% scored 3) and staining intensity (0 for negative; 1 for weak; 2 for moderate; 3 for strong) . The final score is calculated by multiplying these values, with high expression typically defined as scores >3 and low expression as scores 0-3 . This methodical approach enables consistent evaluation across research studies and comparison between different tissue samples.

What are the optimal conditions for ITGB6 antibody use in immunohistochemistry?

For immunohistochemical applications, researchers have successfully employed ITGB6 antibodies at 1/500 dilution in paraffin-embedded tissue samples . Validation studies have demonstrated effective ITGB6 staining in mouse duodenum and testis tissues using this dilution . When conducting IHC experiments, tissues should be processed using standard paraffin embedding techniques, and antigen retrieval methods should be optimized depending on the specific antibody manufacturer's recommendations. Double-blind evaluation by experienced pathologists is recommended to ensure objective scoring, particularly when correlating expression with clinical outcomes .

How can ITGB6 expression data be correlated with clinical outcomes?

To correlate ITGB6 expression with clinical outcomes, researchers should implement rigorous statistical analysis of expression data against patient survival metrics. Kaplan-Meier survival curves can be generated using mRNA expression data with thresholds set at one standard deviation above the mean (z-score ± 1.0) . This approach has revealed that ITGB6 serves as a potent marker of poor prognosis in multiple cancer types. For example, in pancreatic adenocarcinoma, high ITGB6 expression correlates with significantly reduced median survival (16.79 months versus 21.88 months in patients with low ITGB6 expression, p<0.004) . Similar approaches can be applied to other cancer types to establish prognostic relevance.

What controls should be included when using ITGB6 antibodies in experimental studies?

Best practices for ITGB6 antibody experiments include several critical controls. Positive controls should utilize tissues with known ITGB6 expression (such as duodenum or certain cancer cell lines). Negative controls should include both isotype controls (using non-specific antibodies of the same isotype) and tissues known to lack ITGB6 expression. For genetic studies examining ITGB6 function, comparing wild-type cells with ITGB6 knockout or knockdown models is essential. When studying ITGB6's role in immunomodulation, researchers should include both immune cell-present and immune cell-depleted conditions to isolate ITGB6-specific effects .

How does ITGB6 expression influence tumor immune microenvironment?

ITGB6 expression significantly alters the tumor immune microenvironment by inhibiting antitumor T-cell responses. In colorectal cancer models, ITGB6 overexpression reduced the proportion of CD8+ T cells in tumors and diminished their functional capacity, as evidenced by decreased granzyme B, perforin, IFN-γ, and TNF-α expression . This immunosuppressive effect extends beyond the tumor site, with ITGB6 downregulating IFN-γ expression in CD8+ T cells isolated from spleens and draining lymph nodes . Single-cell RNA sequencing analysis of ITGB6 knockout versus control tumors has revealed changes in immune cell population distributions, with decreased percentages of monocytes/macrophages/dendritic cells and γδT cells in ITGB6-deficient tumors . These findings indicate ITGB6's multifaceted role in shaping immune cell recruitment and function.

What is the relationship between ITGB6 expression and response to immunotherapy?

ITGB6 expression strongly correlates with resistance to immune checkpoint blockade therapy. Research has demonstrated that ITGB6 expression in colorectal cancer acts as an immune evasion strategy that causes inhibition of antitumor immune responses and resistance to immune checkpoint blockade therapy through TGF-β activation . Importantly, antibody-mediated inhibition of integrin αvβ6 can spark a potent cytotoxic T-cell response and overcome resistance to programmed cell death protein 1 (PD-1) blockade therapy in ITGB6-expressing tumors . The relationship between ITGB6 expression and therapy response can be quantified using the ROC Plotter tool, which enables comparison of expression levels between immunotherapy responders and non-responders .

How can ITGB6 serve as a prognostic biomarker in different cancer types?

ITGB6 demonstrates significant prognostic value across multiple cancer types. Research has established that enhanced expression of integrin αvβ6 is associated with aggressive disease and poor prognosis in numerous carcinoma entities . Specific findings include:

These findings suggest that ITGB6 expression analysis could serve as a valuable addition to standard prognostic assessments in clinical oncology .

How can ITGB6 targeting be combined with other cancer therapies?

Combination therapeutic approaches involving ITGB6 targeting show promising synergistic effects. In head and neck squamous cell carcinoma models, combining ITGB6 knockout with anti-CD276 antibody treatment produced superior therapeutic outcomes compared to either intervention alone. Tumors from mice with ITGB6 depletion receiving α-CD276 treatment decreased by 53.24% in size . This synergistic effect appears to work through enhanced T-cell infiltration and activation, as ITGB6 knockout significantly improved CD8+ T cell infiltration into tumors, and this effect was further amplified by anti-CD276 therapy . When designing combination studies, researchers should consider analyzing both tumor growth kinetics and immune cell phenotyping to fully characterize the mechanism of synergy.

What molecular mechanisms underlie ITGB6's role in therapy resistance?

ITGB6's role in therapy resistance is primarily mediated through TGF-β activation. As one of the major physiological activators of TGF-β, integrin αvβ6 controls the release of this immunosuppressive cytokine from its latent form . Mechanistically, this occurs through R-G-D-dependent interaction with the Latency-associated peptide (LAP) . The activated TGF-β subsequently inhibits the antitumor T-cell response, creating an immunosuppressive microenvironment that limits the efficacy of immunotherapies . Additionally, ITGB6 may promote cancer cell invasion through mechanisms involving clathrin-mediated endocytosis of the integrin αvβ6 complex . Understanding these molecular pathways provides rational targets for intervention to overcome therapy resistance.

How can genetic manipulation of ITGB6 inform therapeutic antibody development?

Genetic manipulation studies of ITGB6 provide critical insights for therapeutic antibody development. Research utilizing Itgb6 conditional knockout mouse models has demonstrated that genetic ablation of ITGB6 partially mitigates tumor progression and significantly enhances the efficacy of immunotherapies . In head and neck cancer models, ITGB6-cKO mice receiving anti-CD276 therapy showed substantially enhanced therapeutic responses compared to control mice . Similarly, in colorectal cancer models, ITGB6 knockout rendered tumors susceptible to PD-1 blockade . These genetic studies reveal that effective therapeutic antibodies should aim to completely neutralize ITGB6 function, potentially by blocking its interaction with ITGAV or preventing binding to its ligands. Characterization of the binding epitopes and functional effects of candidate therapeutic antibodies should be benchmarked against the phenotypes observed in genetic knockout models.

What are common technical challenges when working with ITGB6 antibodies?

Researchers frequently encounter several technical challenges when working with ITGB6 antibodies. Specificity concerns may arise due to cross-reactivity with other integrin family members that share sequence homology. Additionally, the conformational state of integrin αvβ6 (active versus inactive) can affect antibody binding and experimental outcomes. To address these challenges, researchers should:

• Validate antibody specificity using ITGB6 knockout or knockdown controls

• Consider fixation methods carefully, as these may alter integrin conformation

• Include appropriate positive controls (known ITGB6-expressing tissues)

• Test multiple antibody clones targeting different epitopes

• Optimize antibody concentration through careful titration experiments

These methodological considerations help ensure reliable and reproducible results when studying ITGB6 expression and function.

How can researchers determine the functional effects of ITGB6 antibodies?

To evaluate the functional effects of ITGB6 antibodies, researchers should employ a multi-faceted approach that extends beyond simple binding assays. Assessment should include:

• TGF-β activation assays to measure the antibody's ability to inhibit ITGB6-mediated TGF-β release

• T-cell co-culture experiments to assess reversal of immunosuppression

• Tumor growth studies in immunocompetent mouse models

• Combination studies with established immunotherapies like PD-1 inhibitors

Research has demonstrated that effective anti-ITGB6 antibodies should spark a potent cytotoxic T-cell response and overcome resistance to checkpoint blockade therapy . Functional validation is essential, as mere binding to ITGB6 does not guarantee inhibition of its immunosuppressive activities.

What considerations are important when designing experiments to study ITGB6's role in immune evasion?

When designing experiments to investigate ITGB6's role in immune evasion, researchers should consider several critical factors:

• Use immunocompetent models, as ITGB6's effects are largely immune-mediated

• Include appropriate controls (ITGB6 knockout/knockdown)

• Analyze multiple immune cell populations (CD8+ T cells, CD4+ T cells, myeloid cells)

• Assess both cell proportions and functional markers (cytokines, granzymes)

• Consider spatial distribution of immune cells within tumors (not just total numbers)

• Compare effects in both primary tumors and metastatic sites

It's particularly important to evaluate CD8+ T cell infiltration and activation, as research has shown that ITGB6 knockout significantly enhances CD8+ T cell infiltration into tumors, and this effect can be further amplified by combination with immunotherapies . Additionally, single-cell RNA sequencing approaches can provide comprehensive insights into the complex changes in tumor immune microenvironment induced by ITGB6 manipulation .